How much does a box of Mobotinib (Mobosetinib) cost in India?

Mobocertinib (Mobocertinib), trade name Exkivity, is a third-generation tyrosine kinase inhibitor (TKI) developed by Japan's Takeda Pharmaceutical Co., Ltd. It is specifically designed to treat EGFR (epidermal growth factor receptor) exon 20 insertion mutations in patients with non-small cell lung cancer (NSCLC). This type of mutation often shows resistance to traditional EGFR-TKI drugs, and mobosetinib offers a new treatment option by irreversibly binding to and inhibiting the tyrosine kinase activity of these mutants.

Currently, Mobotinib (Mobosetinib) has been launched in China, but it has not yet been included in medical insurance. This means that patients need to pay for the drug out of pocket, which is relatively expensive. Purchasing Mobotinib (Mobosetinib) domestically may involve some difficulties, and patients often need to consult their local hospital pharmacy or specialist drug supply facility to obtain the drug. Since there is no medical insurance reimbursement, patients need to bear all costs themselves, so the financial burden is heavy.

In foreign markets, in addition to the original drug, generic drugs of Mobotinib (mobosetinib) produced by Takeda in Japan are also available. The original drug is sold in Hong Kong and other places, and the price is about 7,000 to 8,000 yuan. In contrast, generic drugs mainly come from Laos and Bangladesh. The price of these generic drugs is about more than 3,000 yuan, about half of the original drugs. Although the price is low, these generic drugs are basically the same as the original drugs in terms of ingredients and efficacy, but patients should make sure to purchase them through formal channels to ensure the safety and effectiveness of the drugs.

It should be noted that there is currently no officially launched Indian version of Mobosetinib generics on the market. Although India has a high reputation and market share in the production of generic drugs, formobosetinib, only the generic drugs produced in Laos and Bangladesh are widely recognized and used at this stage. Therefore, patients should avoid buying the so-called "Indian version"Mobosetinib (Mobosetinib) when purchasing generic drugs to prevent buying drugs that have not been certified through formal channels.